TY - JOUR
T1 - Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
AU - Bae, Soo Youn
AU - Nam, Seok Jin
AU - Jung, Yongsik
AU - Lee, Sae Byul
AU - Park, Byung Woo
AU - Lim, Woosung
AU - Jung, Sung Hoo
AU - Yang, Hsien Wen
AU - Jung, Seung Pil
N1 - Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Purpose: TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC. Methods: A total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 ‘p53-positive (+) TNBC’ patients and 5062 ‘p53-negative (−) TNBC’ patients. Results: In univariate analysis, p53(+) TNBC had a worse prognosis than p53(−) TNBC in patients not receiving chemotherapy (P = 0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(−) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(−) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(−) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(−) TNBC, there was no risk reduction effect by chemotherapy. Conclusion: The prognosis of p53(+) TNBC has worse than p53(−) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(−) TNBC.
AB - Purpose: TP53 mutation is the most common mutation in breast cancer, and it is considered a target marker of triple-negative breast cancer (TNBC). We investigated whether expression of p53 detected by immunochemical staining predicts the chemotherapy response of TNBC. Methods: A total of 11,393 TNBC patients who had between stage I and stage III enrolled in the Korean Breast Cancer Society Registry database from January 1, 2000 to December 31, 2015. There were 6,331 ‘p53-positive (+) TNBC’ patients and 5062 ‘p53-negative (−) TNBC’ patients. Results: In univariate analysis, p53(+) TNBC had a worse prognosis than p53(−) TNBC in patients not receiving chemotherapy (P = 0.003). However, there was no difference in prognosis between p53(+) TNBC and p53(−) TNBC for patients receiving chemotherapy. In multivariate analysis adjusted for age and stage, the risk of p53(+) TNBC was 1.84 times higher than that of p53(−) TNBC in the non-chemotherapy group. However, there was no difference between p53(+) TNBC and p53(−) TNBC in patients receiving chemotherapy. In p53(+) TNBC, the risk was 0.6-fold lower when chemotherapy was administered than when chemotherapy was not administered. However, in p53(−) TNBC, there was no risk reduction effect by chemotherapy. Conclusion: The prognosis of p53(+) TNBC has worse than p53(−) TNBC, but the risk for survival was significantly reduced with chemotherapy. It suggests that p53(+) TNBC would be more sensitive to chemotherapy than p53(−) TNBC.
KW - Chemotherapy
KW - Immunohistochemistry
KW - P53
KW - Prognosis
KW - Triple-negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85052092591&partnerID=8YFLogxK
U2 - 10.1007/s10549-018-4928-2
DO - 10.1007/s10549-018-4928-2
M3 - Article
C2 - 30132220
AN - SCOPUS:85052092591
SN - 0167-6806
VL - 172
SP - 437
EP - 444
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -
